Centre for Applied Medical Research, University of Navarra, Pamplona, Spain.
Br J Haematol. 2010 Apr;149(1):111-7. doi: 10.1111/j.1365-2141.2009.08060.x. Epub 2010 Jan 18.
Traces of activated factor VII (FVIIa) are required to maintain haemostasis. Activated factor X (FXa) is the main activator of FVII in the absence of tissue factor. However, little is known about how this mechanism is regulated. We and others reported the interaction between FVII and the endothelial cell protein C receptor (EPCR). We have analysed the role of EPCR in the FXa-dependent FVIIa generation. Activation was performed on the surface of human aortic endothelial cells in the presence or absence of a blocking anti-EPCR monoclonal antibody (mAb). Western-blot analyses revealed that FVII activation was increased twofold upon EPCR blocking. Kinetic analyses revealed that blocking doubled the catalytic efficiency for activation. Protein C was unable to mimic the effect of the anti-EPCR mAb on activation. Surface plasmon resonance experiments revealed that binding of EPCR and phospholipids to FVII were mutually exclusive. The 50% inhibitory concentration value for phospholipids to reduce the binding of FVIIa to EPCR was 57.67 +/- 0.11 micromol/l. Immunofluorescence experiments showed that EPCR and phosphatidylserine are located at different regions of the cell surface. We propose that EPCR downregulates FVII activation by moving it from phosphatidylserine-rich regions. In summary, this study described a new anticoagulant role for EPCR.
激活的因子 VII(FVIIa)痕迹对于维持止血是必需的。在不存在组织因子的情况下,激活的因子 X(FXa)是 FVII 的主要激活剂。然而,人们对这种机制如何被调节知之甚少。我们和其他人报道了 FVII 与内皮细胞蛋白 C 受体(EPCR)之间的相互作用。我们分析了 EPCR 在 FXa 依赖性 FVIIa 生成中的作用。在存在或不存在阻断性抗 EPCR 单克隆抗体(mAb)的情况下,在人主动脉内皮细胞表面上进行了激活。Western blot 分析显示,EPCR 阻断使 FVII 激活增加了两倍。动力学分析显示,阻断将激活的催化效率提高了一倍。蛋白 C 不能模拟抗 EPCR mAb 对激活的作用。表面等离子体共振实验表明,EPCR 和磷脂与 FVII 的结合是相互排斥的。降低 FVIIa 与 EPCR 结合的磷脂的 50%抑制浓度值为 57.67 +/- 0.11 微摩尔/升。免疫荧光实验表明,EPCR 和磷脂酰丝氨酸位于细胞表面的不同区域。我们提出,EPCR 通过将其从富含磷脂酰丝氨酸的区域中移出,从而下调 FVII 激活。总之,本研究描述了 EPCR 的一种新的抗凝作用。